ArticleHernia : the journal of hernias and abdominal wall surgery2025
Mesh removal and ventral hernia repair with long-term absorbable mesh in case of mesh infection.
Article in Hernia : the journal of hernias and abdominal wall surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Histopathological features and tissue remodeling in chronic abdominal wall mesh infection - a clinicopathological study.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMesh infection after ventral hernia repair remains rare, but often necessitates mesh removal. This study evaluated the short- and long-term outcomes of a strategy involving explantation of the infected mesh and insertion of a long-term absorbable mesh in acute (AMI) and chronic mesh infections (CMI).
methodsA retrospective study was performed in two tertiary centers (01.01.2017-31.12.2024). All consecutive patients with ventral mesh infection who underwent mesh explantation followed by placement of a long-term absorbable poly-4-hydroxybutyrate mesh were included. Primary endpoint was hernia recurrence rate. AMI was defined as mesh infection within 90 postoperative days.
resultsTwenty-nine patients were included: 14 AMI/15 CMI. Meshes were intraperitoneal in 9/14 (64%) AMI and in 13/15 (87%) CMI patients. Twelve (86%) and 13 patients (87%) had a new mesh implanted in the retromuscular space in the AMI and CMI groups, respectively. Four (28%) and 3 patients (21%) needed posterior component separations in the AMI and CMI groups. Median hospital stays were 10 (5-15) and 7 days (5-13) in both groups. Nine patients in each group (64%/60%) developed postoperative complications. Hernia recurrence rates were 3/14 (21%) and 0 in the AMI and CMI groups (mean follow-up 17 months). One mesh had to be explanted in the AMI group (0 in the CMI group).
conclusionsThe presented strategy was associated with high short-term morbidity, but good long-term results, with low mesh explantation and hernia recurrence rates. A longer follow-up and inclusion of more patients is required to assess the risk of hernia recurrence and reinfection with greater hindsight.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.